Skip to content
§ Article

FedRAMP continuous monitoring. The monthly and annual obligations.

FedRAMP continuous monitoring explained: the monthly scans, POA&M updates, remediation deadlines, and annual 3PAO reassessment required to keep your authorization.

Getting a FedRAMP authorization is the milestone every team aims for. Keeping it is the part that catches them off guard. The day your authorization to operate is granted, a recurring set of obligations begins, and it runs for as long as you hold the authorization. That ongoing work is continuous monitoring, and most teams underbudget it.

Here is what FedRAMP continuous monitoring actually requires, month to month and year to year, and where the recurring cost hides.

What continuous monitoring is.

A FedRAMP authorization is a point-in-time statement that your system met the security bar on the day it was assessed. Systems change every day after that. Continuous monitoring, usually shortened to ConMon, is how FedRAMP confirms the system still meets the bar over time.

The obligation runs on a fixed cadence. Some tasks are monthly, some are annual, and some are triggered by changes to the system. Miss the cadence and your authorization is at risk, regardless of how secure the system actually is. ConMon is the proof that the security held, delivered on schedule.

The monthly obligations.

Every month, an authorized CSP owes its agency a set of continuous monitoring deliverables. Two pieces sit at the center of the package.

Vulnerability scans.

You scan the full authorization boundary at least once a month. That covers operating systems, databases, web applications, containers, and service configurations. The scans reach the entire inventory inside the boundary, or an approved sampling where FedRAMP allows one. The results go to your agency every month.

The POA&M.

Every vulnerability a scan finds becomes a line item on your Plan of Action and Milestones, the POA&M. Each unique finding is tracked on its own, with a remediation date attached. The POA&M is updated and submitted monthly alongside the scans.

Remediation runs on deadlines set by severity. A High finding gets 30 days. A Moderate finding gets 90. A Low finding gets 180. A finding that blows its deadline shows up in the next monthly package, where the agency and the assessor both see it. The POA&M is the clearest single signal of whether a CSP is keeping up.

The change-driven obligations.

Some obligations do not wait for the calendar. Material changes to an authorized system carry their own process.

A significant change, meaning anything that alters the security posture or the authorization boundary, requires a Significant Change Request before it ships. You describe the change, its security impact, and how it will be assessed, then you wait for agency approval. Shipping a boundary-altering change without that approval is its own finding, separate from anything a scan would catch.

This is where fast-moving SaaS teams feel FedRAMP most. The product roadmap and the authorization boundary are now linked, and engineering velocity has a compliance checkpoint it did not have before.

The annual obligations.

Once a year, continuous monitoring scales up to a full reassessment.

A 3PAO performs an annual assessment of a subset of the controls, on top of the monthly evidence you have produced all year. Going in, you bring the core authorization package current: the System Security Plan and its appendices, the POA&M, and the system inventory. An annual penetration test feeds the assessment as well.

The annual assessment is lighter than the initial authorization. It is still a scheduled, assessor-led checkpoint that confirms a year of monthly evidence adds up to a system worth keeping authorized. Teams that treat ConMon as a monthly discipline walk in with the evidence already in hand. Teams that let it slide spend the weeks before the assessment reconstructing a year of proof.

What this costs, and where the cost hides.

The headline cost of FedRAMP is the push to initial authorization. The cost that surprises teams is the one that recurs.

Continuous monitoring is a standing operational load. Monthly scanning and POA&M management, the engineering hours to remediate findings inside their deadlines, the annual 3PAO assessment fee, and the annual penetration test all repeat for as long as you hold the authorization. A team that modeled FedRAMP as a one-time project, and not a permanent line in the budget, feels it in year two.

The deeper cost is attention. ConMon pulls the same senior engineers who built the authorization back to it every month. Left manual, it becomes a permanent tax on the roadmap.

Where the monthly load actually comes from.

Most of the recurring work is not the scanning. Tools scan. The work is turning raw scan output and live system state into evidence an assessor accepts: current, traceable, and matched to the control it supports.

This is the same evidence problem the initial authorization posed, now running every month, against the same control baseline you authorized at.

Keep the authorization you worked for.

Continuous monitoring is the price of staying in the federal market once you have entered it. The monthly cadence, the remediation deadlines, and the annual reassessment are fixed. What varies is whether producing that evidence is a monthly scramble or a byproduct of running the system.

SentrIQ converts live system state into assessor-ready authorization artifacts. The same engine that drives a package to authorization keeps producing the monthly evidence continuous monitoring demands, mapped to the FedRAMP controls behind each finding. The authorization you spent months earning is worth keeping on schedule.

§ Newsletter

The FedRAMP brief, weekly.

One short email every Monday. New articles and what changed in federal compliance.

§ Readiness check

Where does your readiness sit today?

Take the free 5-minute readiness assessment.

Run it
§ Next step

Run the free 5-minute readiness assessment.

Ten questions, a tailored readiness score, and the gaps you'd hit during a 3PAO assessment.